Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma · Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
This study is a prospective open-label randomized clinical trial. Following informed consent eligible LASCCHN patients (n=100) planned for CRT will be stratified by tumor p16 status and then randomized in a 1:1 fashion to either concurrent HD cisplatin or concurrent weekly LD cisplatin.
This description comes directly from the study's public registry record.
Sara Kuruvilla, MD · (519)685-8500 · sara@kuruvilla@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| Juravinski Cancer Centre | Hamilton, Ontario, Canada | Recruiting |
| London Regional Cancer Program | London, Ontario, Canada | Active Not Recruiting |
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03649048